Discover and read the best of Twitter Threads about #Teplizumab

Most recents (6)

Abro 🧵para hacer un recuento de lo que el #Año2022 nos dejó:
1. La aprobación por la @US_FDA en Noviembre del Tzield (#Teplizumab), un anticuerpo monoclonal anti-CD3 que retrasa la aparición de la #diabetes tipo 1.
2. La publicación en @ScienceMagazine de la fase 1 del ensayo clínico con la #vacuna eOD-GT8-AS01B para prevenir el #VIH, que indujo la sintesis de #anticuerpos neutralizantes vs el virus, en el 97% de los que fueron vacunados.
3. El #Daxxify una nueva forma de toxina botulínica tipo A, cuyo efecto tiene una duración de hasta 6 meses. El efecto del #botox es de alrededor de 3 meses.
Read 27 tweets
🧵#diabetes prevention : are we on the right track?
Here are the players in the development of #T1D 👇
-M. Knip

#ISPAD #ISPAD2022 #dedoc°voices #NothingAboutUsWithoutUs #patientvoice #payitforward @dedocORG @ispad_org 1/n
#diabetes prevention : are we on the right track?
The different stages of #betaCells autoimmunity:
1⃣ Normoglycemia
2⃣ Presymptomatic dysglycemia
3⃣ Symptomatic dysglycemia
Primary prevention shld start during pregnancy.
-M. Knip

#ISPAD2022 #dedoc°voices @dedocORG @ispad_org 2/n
#diabetes prevention : are we on the right track?
Early life infection may be the initiator of the endotype. There is a step autoantibodies decline among those diagnosed before 7yo.
-M. Knip

#ISPAD2022 #dedoc°voices #payitforward @dedocORG @ispad_org 3/n
Read 7 tweets
Since people are going gaga over the Vertex Pharma T1D stem-cell announcement yesterday, here's a quick review of where we are, and how we got here: 🧵👇
Islet transplants have been happening for more than two decades: pubmed.ncbi.nlm.nih.gov/10911004/
We've been able to make islets and beta cells from stem cells for quite a while, too. Here's a review article from 2012 (yes, almost a decade ago) summarizing progress on stem-cell derived beta cells up to that point: ncbi.nlm.nih.gov/pmc/articles/P…
Read 21 tweets
Update #ProventionBio #Provention $PRVB #teplizumab. For a summary of AdCom etc. see thread below. I am not involved with the company but have other conflicts of interest. All is based on public information and personal opinion.
Recap: Company has Breakthrough Therapy Designation and Priority Review, an AdCom vote 10-7 in favour for “delay of Type 1 diabetes #T1D”, and got a CRL stating CMC problems and failure to demonstrate PK/PD comparability between the studied Lilly-produced
and to-be commercialized ACG-produced teplizumab drug product (DP). A PK/PD substudy in the ongoing phase 3 PROTECT trial of 2 x 12 days of IV teplizumab 6 months apart in new-onset T1D has been completed (AGC Biologics DP ca. 30 patients, Lilly DP ca. 130 patients).
Read 11 tweets
Second part: on #ProventionBio #Provention $PRVB #anti-CD3 monoclonal antibody #teplizumab under #FDA consideration for the “delay of clinical #Type1Diabetes #T1D in at-risk individuals”.

Upcoming questions cont’d:
(4) If risk/benefit is acceptable, which target population is deemed suitable by the FDA? There were proponents of 3 options in EMDAC: (a) Stage 1 + 2, (b) Stage 2, or (c) Stage 2 + family Hx of T1D (= inclusion criteria of TN-10).
(a) is unlikely, I think, my vote is with (b). With regards to age, I think >8 years (as in TN-10) will be a requirement, given the SEs associated with teplizumab.
Read 26 tweets
Thread on #ProventionBio #Provention $PRVB and their flagship #antiCD3 monoclonal antibody #teplizumab under #FDA consideration for the “delay of clinical #Type1Diabetes #T1D in at-risk individuals”. I have no connection to the company – but I do have COIs. No recommendations
or claims of accuracy, just a summary of the status quo and personal opinion. Assume I’m biased. All public information. Feel free to correct me. For references & links, contact me. Some pictures are copies from public PRVB presentations/FDA briefing docs.
*Summary*

PRVB are seeking approval of 14-day IV teplizumab for the delay of T1D. Teplizumab is a humanised Fc-mutated anti-CD3 monocl Ab that, simply put, turns autoreactive T-cells (regardless of antigen) into exhausted T-cells

(PRVB corporate presentation slide) Image
Read 27 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!